Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane

Figure 2

Effect of EGCG and SFN on the efficacy of cisplatin to cisplatin-sensitive (A2780) and cisplatin-resistant (A2780/CP20) ovarian cancer cells. (a) and (b). EGCG and SFN combinational treatment can enhance the efficacy of cisplatin in both cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. (c) and (d) Morphology of ovarian cancer cells after 3 days of EGCG, SFN, or cisplatin treatment. EGCG: 10 μM, SFN: 5 μM, ES: EGCG 10 μM + SFN 5 μM, Cis: cisplatin, 1.5 μM cisplatin for A2780, 8 μM cisplatin for A2780/CP20, ESCis: EGCG 10 μM + SFN 5 μM + cisplatin (1.5 μM cisplatin for A2780, 8 μM cisplatin for A2780/CP20). Magnification: 100X. ^∗𝑃<0.05, ^∗∗𝑃<0.01, ^∗∗∗𝑃<0.001.

(a)

(b)

(c)

(d)